Literature DB >> 11752176

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.

Bianca R Mothé1, Helen Horton, Donald K Carter, Todd M Allen, Max E Liebl, Pam Skinner, Thorsten U Vogel, Sarah Fuenger, Kathy Vielhuber, William Rehrauer, Nancy Wilson, Genoveffa Franchini, John D Altman, Ashley Haase, Louis J Picker, David B Allison, David I Watkins.   

Abstract

Cytotoxic T-lymphocyte (CTL) responses are thought to control human immunodeficiency virus replication during the acute phase of infection. Understanding the CD8(+) T-cell immune responses early after infection may, therefore, be important to vaccine design. Analyzing these responses in humans is difficult since few patients are diagnosed during early infection. Additionally, patients are infected by a variety of viral subtypes, making it hard to design reagents to measure their acute-phase immune responses. Given the complexities in evaluating acute-phase CD8(+) responses in humans, we analyzed these important immune responses in rhesus macaques expressing a common rhesus macaque major histocompatibility complex class I molecule (Mamu-A*01) for which we had developed a variety of immunological assays. We infected eight Mamu-A*01-positive macaques and five Mamu-A*01-negative macaques with the molecularly cloned virus SIV(mac)239 and determined all of the simian immunodeficiency virus-specific CD8(+) T-cell responses against overlapping peptides spanning the entire virus. We also monitored the evolution of particular CD8(+) T-cell responses by tetramer staining of peripheral lymphocytes as well as lymph node cells in situ. In this first analysis of the entire CD8(+) immune response to autologous virus we show that between 2 and 12 responses are detected during the acute phase in each animal. CTL against the early proteins (Tat, Rev, and Nef) and against regulatory proteins Vif and Vpr dominated the acute phase. Interestingly, CD8(+) responses against Mamu-A*01-restricted epitopes Tat(28-35)SL8 and Gag(181-189)CM9 were immunodominant in the acute phase. After the acute phase, however, this pattern of reactivity changed, and the Mamu-A*01-restricted response against the Gag(181-189)CM9 epitope became dominant. In most of the Mamu-A*01-positive macaques tested, CTL responses against epitopes bound by Mamu-A*01 dominated the CD8(+) cellular immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752176      PMCID: PMC136839          DOI: 10.1128/jvi.76.2.875-884.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Vaccination with Rev and Tat against AIDS.

Authors:  A D Osterhaus; C A van Baalen; R A Gruters; M Schutten; C H Siebelink; E G Hulskotte; E J Tijhaar; R E Randall; G van Amerongen; A Fleuchaus; V Erfle; G Sutter
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

4.  Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues.

Authors:  P J Skinner; M A Daniels; C S Schmidt; S C Jameson; A T Haase
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

6.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.

Authors:  M A Altfeld; A Trocha; R L Eldridge; E S Rosenberg; M N Phillips; M M Addo; R P Sekaly; S A Kalams; S A Burchett; K McIntosh; B D Walker; P J Goulder
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

9.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

10.  Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.

Authors:  P J Goulder; M A Altfeld; E S Rosenberg; T Nguyen; Y Tang; R L Eldridge; M M Addo; S He; J S Mukherjee; M N Phillips; M Bunce; S A Kalams; R P Sekaly; B D Walker; C Brander
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  64 in total

1.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response.

Authors:  Thomas C Friedrich; Christopher A Frye; Levi J Yant; David H O'Connor; Nancy A Kriewaldt; Meghan Benson; Lara Vojnov; Elizabeth J Dodds; Candice Cullen; Richard Rudersdorf; Austin L Hughes; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.

Authors:  Konstantin Virnik; Yisheng Ni; Ira Berkower
Journal:  Vaccine       Date:  2012-07-06       Impact factor: 3.641

5.  Tat(28-35)SL8-specific CD8+ T lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay.

Authors:  John T Loffredo; Eva G Rakasz; Juan Pablo Giraldo; Sean P Spencer; Kelly K Grafton; Sarah R Martin; Gnankang Napoé; Levi J Yant; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius.

Authors:  Roger W Wiseman; Jason A Wojcechowskyj; Justin M Greene; Alex J Blasky; Tobias Gopon; Taeko Soma; Thomas C Friedrich; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

8.  Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.

Authors:  Miranda Z Smith; C Jane Dale; Robert De Rose; Ivan Stratov; Caroline S Fernandez; Andrew G Brooks; Jason Weinfurter; Kendall Krebs; Cara Riek; David I Watkins; David H O'connor; Stephen J Kent
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

10.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.